Structure Therapeutics Inc. (GPCR) /
The cash flow of Structure Therapeutics Inc. over the past 4 years
Chart Structure Therapeutics Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2022–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Structure Therapeutics Inc.'s operating cash flow was -$222.2M and its capital expenditures $3.61M, leaving free cash flow of -$225.81M. Free cash flow was below zero in all 4 years shown. It ranged from -$225.81M in fiscal 2025 to -$46.27M in fiscal 2022. Capital expenditures were highest in fiscal 2025, at $3.61M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$222.2M | $3.61M | -$225.81M |
| 2024ended Dec 31, 2024 | -$116.64M | $1.29M | -$117.93M |
| 2023ended Dec 31, 2023 | -$79.49M | $2.17M | -$81.66M |
| 2022ended Dec 31, 2022 | -$46.12M | $155K | -$46.27M |
Fiscal years as Structure Therapeutics Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Structure Therapeutics Inc.
- The profitability of Structure Therapeutics Inc.
- The debt of Structure Therapeutics Inc.
- All of Structure Therapeutics Inc.'s financials, charted
Companies of a similar size
- BCOBRINK’S CO
- STWDStarwood Property Trust, Inc.
- JOBYJoby Aviation, Inc.
- SIGSIGNET JEWELERS LIMITED
- OKLOOklo Inc.
Not investment advice. This page shows what Structure Therapeutics Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.